why choose us

First received: April 13, 2023

Clinical Trial: Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

Study Status: Completed

Recruit Status: RECRUITING

Condition: FXI

Study Type: INTERVENTIONAL


Official Title: Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administer

Brief Summary: The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.

Read more